The lack, need, and opportunities for decision-making and informational tools to educate primary-care physicians and women about breast cancer chemoprevention

Cancer Prevention Research

Volumn 3, Issue 6, 2010, Pages 686-688

  Ravdin, Peter M ^a  

^a University of Texas Health Science Center at San Antonio   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; RALOXIFENE; TAMOXIFEN; ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

BREAST CANCER; CANCER RISK; CHEMOPROPHYLAXIS; CLINICAL DECISION MAKING; FEMALE; GENERAL PRACTITIONER; HUMAN; INTERNET; MEDICAL INFORMATION; OUTCOME ASSESSMENT; PATIENT EDUCATION; POSTGRADUATE EDUCATION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; ADENOCARCINOMA; BREAST NEOPLASMS; CLINICAL PRACTICE; DECISION SUPPORT SYSTEM; DRUG UTILIZATION; EDUCATION; INCIDENCE; MULTICENTER STUDY (TOPIC); NEOPLASMS, HORMONE-DEPENDENT; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; STATISTICS AND NUMERICAL DATA; TRENDS;

ADENOCARCINOMA; BREAST NEOPLASMS; DECISION SUPPORT TECHNIQUES; DRUG UTILIZATION; ESTROGENS; FEMALE; HUMANS; INCIDENCE; INTERNET; MULTICENTER STUDIES AS TOPIC; NEOPLASMS, HORMONE-DEPENDENT; PATIENT EDUCATION AS TOPIC; PHYSICIAN'S PRACTICE PATTERNS; PHYSICIANS, FAMILY; RALOXIFENE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; RISK REDUCTION BEHAVIOR; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; PRACTICE PATTERNS, PHYSICIANS'; RALOXIFENE HYDROCHLORIDE;

EID: 77953496676     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-10-0100     Document Type: Review

References (20)

1. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-88.
2. Vogel VG, Costantino JP, Wickerham DL, et al. Update of the national surgical adjuvant breast and bowel project study of tamoxifen and raloxifene (STAR) P-2 trial: preventing breast cancer. Cancer Prev Res 2010;3:696-706.
3. Visvanathan K, Chlebowski RT, Hurley P, et al. American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol 2009;27:3235-58.
4. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989;81:1879-86.
5. Freedman AN, Graubard BI, Rao SR, McCaskill-Stevens W, Ballard-Barbash R, Gail MH. Estimates of the number of U.S. women who could benefit from tamoxifen for breast cancer chemoprevention. J Natl Cancer Inst 2003;95:526-32. (Pubitemid 36511623)
6. Drugs@FDA. Available from: http://www.accessdata.fda.gov/scripts/cder/ drugsatfda.
7. Waters EA, Cronin KA, Graubard BI, Han PK, Freedman AN. Prevalence of tamoxifen use for breast cancer chemoprevention among U.S. women. Cancer Epidemiol Biomarkers Prev 2010;19:443-6.
8. Armstrong K, Quistberg DA, Micco E, Domchek S, Guerra C. Prescription of tamoxifen for breast cancer prevention by primary care physicians. Arch Intern Med 2006;166:2260-5. (Pubitemid 44748773)
9. Sabatino SA, McCarthy EP, Phillips RS, Burns RB. Breast cancer risk assessment and management in primary care: provider attitudes, practices, and barriers. Cancer Detect Prev 2007;31:375-83.
10. Kaplan CP, Haas JS, Pérez-Stable EJ, Des Jarlais G, Gregorich SE. Factors affecting breast cancer risk reduction practices among California physicians. Prev Med 2005;41:7-15. (Pubitemid 40755058)
11. Port ER, Montgomery LL, Heerdt AS, Borgen PI. Patient reluctance toward tamoxifen use for breast cancer primary prevention. Ann Surg Oncol 2001;8:580-5.
12. Melnikow J, Paterniti D, Azari R, et al. Preferences of Women Evaluating Risks of Tamoxifen (POWER) study of preferences for tamoxifen for breast cancer risk reduction. Cancer 2005;103:1996-2005. (Pubitemid 40605105)
13. Paterniti DA, Melnikow J, Nuovo J, et al. "I'm going to die of something anyway": women's perceptions of tamoxifen for breast cancer risk reduction. Ethn Dis 2005;15:365-72.
14. Day R, Ganz PA, Costantino JP, Cronin WM, Wickerham DL, Fisher B. Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Clin Oncol 1999;17:2659-69. (Pubitemid 29415221)
15. Land SR, Wickerham DL, Costantino JP, et al. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295:2742-51.
16. National Cancer Institute (NCI), National Surgical Adjuvant Breast and Bowel Project (NSABP). Breast Cancer Risk Assessment Tool: an interactive tool to help estimate a woman's risk of developing breast cancer. Available from: http://www.cancer.gov/bcrisktool/about-tool.aspx.
17. Gail MH, Costantino JP, Bryant J, et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 1999;91:1829-46.
18. O'Connor AM, Bennett CL, Stacey D, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev 2009;3:CD001431.
19. Ravdin PM, Siminoff LA, Davis GJ, et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 2001;19:980-91.
20. Adjuvant! Online: decision making tools for health care professionals. Available from: http://www.adjuvantonline.com.